Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2025 ,inter alia, to consider and approve To take on ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts more than Nifty Microcap 250 and 2.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Welcure Drugs & Pharmaceuticals has informed BSE that its Board will meet on 25th September 2025 to consider a Letter of Intent (LOI) from Telexcell Trade PTE LTD, Singapore. Telexcell has proposed acquiring up to 25% equity stake in Welcure at an indicative price of ₹20 per share, which the company describes as a substantial premium over the prevailing market price. The Board will also deliberate on initiating due diligence, finalising definitive agreements, and seeking shareholder approval through postal ballot or general meeting, in line with SEBI, RBI, and FEMA norms. Additionally, the Board will explore strategic growth opportunities in global pharmaceutical and chemical exports by leveraging Telexcell's global trade network. The transaction is expected to strengthen Welcure's balance sheet and expand its global footprint if approved.
If approved, the 25% stake acquisition at a premium could be materially positive for existing shareholders, signalling outside validation and a potential floor under the stock price. Investors should watch for the outcome of the 25th September board meeting and any subsequent open offer obligations under SEBI takeover norms given the 25% threshold.